June 8, 2026 | Startupbusiness features NSBproject’s Digital Health Partnership Study
June 2026 | Media Coverage
Startupbusiness.it — one of Italy’s most authoritative outlets covering startups, innovation, and the European tech ecosystem — has published a dedicated feature on NSBproject’s latest research into the digital health sector, released on June 8, 2026.
The article focuses on a key finding from our analysis: in digital health, defining the right partnerships at the right time is just as important as building the right technology. Getting this sequence wrong is, in many cases, the primary reason promising projects stall before reaching the market.
What the Study Found
The research is based on the observation of approximately 200 European collaboration and partnership cases within the digital health ecosystem, drawing on direct advisory experience, technology development support, and go-to-market engagement across different stages of solution maturity.
The output is a Partnership Playbook — a structured guide for companies, startups, and technology providers navigating a complex, regulated, and highly fragmented market.
Four recurring mistakes emerged from the analysis:
1. Confusing validation with commercialisation. A hospital may be the right partner for testing and validating a technology, but it is not necessarily the entity that will purchase or scale it.
2. Overestimating solution maturity. Many companies pursue commercial partnerships before they have generated sufficient clinical evidence, real-world data, integration proof-of-concept, or regulatory readiness.
3. Failing to identify the real decision-maker. A healthcare partnership involves clinicians, IT departments, procurement, legal teams, and industrial partners. Without clarity on which decision needs to be unlocked, who can make it, and what evidence is required, even promising collaborations tend to stall.
4. Underestimating integration complexity. A technology may function perfectly as a standalone application, yet fail when deployed in a real healthcare environment — where legacy systems, sensitive data, clinical workflows, and regulatory requirements make adoption considerably more demanding.
A Sequential Model, not a Single Alliance
One of the study’s central conclusions is that partnerships in digital health are not interchangeable assets — they are sequential instruments along the technology lifecycle. NSBproject’s model identifies five key phases, from ideation to scale-up, and maps the actors that generate value at each stage:
- Early validation → incubators, innovation hubs, accelerators
- Technology development → test beds and controlled environments
- Clinical validation → hospitals, living labs, clinical centres, testing facilities
- Market entry → clusters, local partners, healthcare operators
- Growth → European networks and investors
This leads to a practical operational checklist for technology providers entering a new market: assess actual maturity before activating partnerships; define the missing asset (clinical data, hospital access, certification, distribution, capital); measure the degree of integration into the clinical pathway; identify who can genuinely unlock the adoption decision; select markets coherent with the development phase; and build a sequence of partnerships rather than a single alliance.
The De-Risking Roadmap Principle
The framework is grounded in a de-risking roadmap approach: every partnership must reduce a concrete obstacle and bring the company closer to the next decision. If it does not, it is not a strategic partnership — it is simply additional overhead.
This matters in the context of a persistent structural challenge: across Europe, between 70% and 75% of research never reaches the market. In Italy, that figure rises to approximately 90%. It is precisely in this gap that technology transfer operators play a decisive role — translating research and innovation into real industrial applications, effective partnerships, and scalable business models.
"In digital health, we see promising technologies stall not because of technical limitations, but because of positioning and partnership errors. Companies tend to seek the most visible or most immediately available partner, without asking which asset is genuinely needed at that stage of the project. In healthcare, accelerating does not mean skipping steps: it means going through them in the right sequence. Success depends not on a single alliance, but on the ability to build a coherent pathway — first clinical validation, then market access, then scalability. This is where technology transfer becomes decisive, because it allows you to read the context and guide decisions in a structured way."
C-Tech Navigator: from Analysis to Actionable Strategy
Alongside its advisory work, NSBproject has developed C-Tech Navigator, a proprietary AI-driven decision-support platform designed to guide go-to-market strategies for R&D projects, analyse competitors and patents, identify alternative collaboration scenarios, and build operational roadmaps. The goal is to turn data, sources, and competitive analyses into concrete indications on partners, markets, risks, timelines, and valorisation pathways.
